Nicole McCarthy

Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

Suparna Wedam, Jennifer A. Low, Sherry X. Yang et al. · Journal of Clinical Oncology · 2006 · 524 citations · Full text

Medicine, Oncology, Pharmacology +14

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sibylle Loibl, Frederik Marmé, Miguel Martín et al. · Journal of Clinical Oncology · 2021 · 324 citations

Medicine, Oncology, Pharmacology +17

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Rebecca Dent, Geoffrey J. Lindeman, Mark Clemons et al. · Breast Cancer Research · 2013 · 185 citations · Full text

Medicine, Oncology, Pharmacology +16

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

John R. Mackey, Manuel Ramos-Vázquez, Oleg Lipatov et al. · Journal of Clinical Oncology · 2014 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17